Spencer Pharmaceutical EBIT

Spencer Pharmaceutical posts a EBIT of $-1.3M as of March 2004. That compares with $-730K in the prior-year period — down 81.9% year over year. That is below the sector sector average of $2.5T. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Spencer Pharmaceutical's EBIT was $-730K. The latest reading is $-1.3M — a 81.9% year-over-year decrease (period ending March 2004). Use the history and growth charts on this page for a longer lookback.

For its sector stocks, a EBIT near $2.5T is typical. Spencer Pharmaceutical's $-1.3M is lower that level. That is roughly 100.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

EBIT is one piece of Spencer Pharmaceutical's financial statement story. At $-1.3M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for SPPH's EBIT usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $2.5T), and (3) consistency with growth and profitability. This page covers the first two; Spencer Pharmaceutical's other metric pages and overview cover the third.